Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Molibresib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 known ✓ | O60885 | 20/20 | 1.00 |
| ▸ | BRD2 known ✓ | P25440 | 2/20 | 1.00 |
| ▸ | BRD3 known ✓ | Q15059 | 1/20 | 1.00 |
| ▸ | BRDT known ✓ | Q58F21 | 1/20 | 1.00 |
| ▸ | SMCHD1 | A6NHR9 | 1/20 | 1.00 |
| ▸ | MYO1G | B0I1T2 | 1/20 | 1.00 |
| ▸ | AIP | O00170 | 1/20 | 1.00 |
| ▸ | AP3B1 | O00203 | 1/20 | 1.00 |
| ▸ | PSMD11 | O00231 | 1/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 1.00 |
| ▸ | SAP18 | O00422 | 1/20 | 1.00 |
| ▸ | KPNA3 | O00505 | 1/20 | 1.00 |
| ▸ | PPP6C | O00743 | 1/20 | 1.00 |
| ▸ | TCERG1 | O14776 | 1/20 | 1.00 |
| ▸ | UBE2L6 | O14933 | 1/20 | 1.00 |
| ▸ | PPP1R12A | O14974 | 1/20 | 1.00 |
| ▸ | U2SURP | O15042 | 1/20 | 1.00 |
| ▸ | SETD1A | O15047 | 1/20 | 1.00 |
| ▸ | ARPC1B | O15143 | 1/20 | 1.00 |
| ▸ | POLR1C | O15160 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Molibresib SCHEMBL12966358 | 1.00 | BRD4 (1.00) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL12671490 | 1.00 | BRD4 (1.00) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL1872390 | 1.00 | BRD4 (1.00) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL19459525 | 0.98 | BRD4 (0.97) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL19459514 | 0.96 | BRD4 (0.92) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL18260664 | 0.95 | BRD4 (0.91) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL18260675 | 0.95 | BRD4 (0.91) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL9998851 | 0.95 | BRD4 (0.91) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL18269839 | 0.94 | BRD4 (0.89) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL15980874 | 0.94 | BRD4 (0.88) | BRD4BRD2SMCHD1MYO1GAIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630883-B2 | Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2026-05-19 | — | — | US | claimed |
| US-20260091021-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2026-04-02 | — | — | US | claimed |
| US-12582613-B2 | Biomimetic, reactive oxygen species-detonable nanoclusters for antirestenotic therapy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-24 | — | — | US | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| US-12533360-B2 | Inhibition of BRD proteins suppresses the phenotype of uterine fibroids | THE UNIVERSITY OF CHICAGO (US) | 2026-01-27 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| WO-2025238176-A1 | COMBINATIONS OF EGFR/ERB AND BET INHIBITORS FOR GASTRIC CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | claimed |
| EP-3664807-B1 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-19 | — | — | EP | claimed |
| US-20250281502-A1 | NEW DRUG APPLICATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-09-11 | — | — | US | claimed |
| EP-3982977-A1 | METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827 | Children's Medical Research Institute (AU) | 2022-04-20 | — | — | EP | claimed |
| US-11298354-B2 | Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-12 | — | — | US | claimed |
| EP-3976195-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3973964-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3969050-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| WO-2022046682-A1 | BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS | MDI BIOLOGICAL LABORATORY (US) | 2022-03-03 | — | — | WO | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | BRD4 13/4885BRD2 11/4885BRD3 18/4885 |
| US-12582613-B2 | Biomimetic, reactive oxygen species-detonable nanoclusters for antirestenotic therapy | EXOSC10, CD47, CD63 | BRD4 1543/4885BRD2 1972/4885BRD3 2517/4885 |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | BRD4 4/4885BRD2 8/4885BRD3 5/4885 |
| US-12630883-B2 | Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes | BCL3, BRD4, BCL6 | BRD4 2/4885BRD2 23/4885BRD3 5/4885 |
| US-20260091021-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | PLK1, BID, ABCB1 | BRD4 4/4885BRD2 235/4885BRD3 69/4885 |
| US-11298354-B2 | Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors | HDAC9, HDAC7, HDAC8 | BRD4 15/4885BRD2 30/4885BRD3 22/4885 |
| US-12533360-B2 | Inhibition of BRD proteins suppresses the phenotype of uterine fibroids | BRD2, BRDT, BRD1 | BRD4 7/4885BRD2 1/4885BRD3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.